Durchbruch

Seite 1 von 8
neuester Beitrag: 29.04.21 15:57
eröffnet am: 23.05.14 14:31 von: apfelrücken Anzahl Beiträge: 192
neuester Beitrag: 29.04.21 15:57 von: Vassago Leser gesamt: 33606
davon Heute: 12
bewertet mit 3 Sternen

Seite:
| 2 | 3 | 4 | 5 | 6 | 7 | 8 | 8   

23.05.14 14:31
3

1455 Postings, 4438 Tage apfelrückenDurchbruch

- The first treatment for the underlying cause of Duchenne muscular dystrophy -

SOUTH PLAINFIELD, New Jersey, May 23, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that following its request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the company's application for a conditional marketing authorization of TranslarnaTM (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged five years and older.



"We are very pleased with the outcome of the CHMP review of Translarna's marketing authorization application (MAA) and the level of engagement we experienced with CHMP members throughout the review process," said Robert J. Spiegel, M.D., Chief Medical Officer of PTC Therapeutics, Inc. "We are grateful to the patients, families, advocacy groups and physicians who have supported PTC Therapeutics through many years of research and development of Translarna. It is important to note that this journey continues through the completion of our Phase 3 Translarna confirmatory trial in nmDMD (ACT DMD) which is a high priority for PTC and the DMD community."

Dr. Craig McDonald, Professor of Physical Medicine and Rehabilitation at the University of California, Davis, who developed and validated the 6-minute walk test as a primary clinical endpoint in Duchenne muscular dystrophy (DMD) stated, "This is a historic day for the DMD community. Translarna is the first treatment for the underlying cause of nonsense mutation DMD to receive a positive opinion from the CHMP. The Phase 2b clinical trial provided strong evidence that Translarna slows disease progression as measured by the 6-minute walk test. A clinically meaningful 31.3 meter benefit in 6-minute walk distance, relative to placebo, was achieved in 48 weeks of treatment in patients five years and older and this was supported by positive trends in multiple secondary efficacy endpoints. In addition, in the prespecified group of patients with less than a 350 meter baseline 6-minute walk distance, a 68 meter benefit was observed in patients treated with 40 mg/kg Translarna given daily, relative to placebo. A conditional approval by the European Commission based on this positive opinion would allow children with nmDMD in the European Union to gain access to Translarna while PTC Therapeutics completes its ongoing confirmatory trial."

The CHMP opinion will form the basis for a European Commission (EC) decision as to whether to formally grant the conditional marketing authorization. The European Commission will review the positive opinion from the CHMP and generally delivers its final decision within three months. The conditional marketing authorization would authorize the company to market Translarna with unified labeling in the 28 countries that are Member States of the European Union, as well as European Economic Area members Iceland, Liechtenstein and Norway.

"We congratulate PTC Therapeutics on this landmark decision by the CHMP," stated Elizabeth Vroom, Chair of United Parent Project Muscular Dystrophy (UPPMD). "We applaud PTC for its dedication to the community and its perseverance in pursuing regulatory options to provide Translarna to patients as rapidly as possible. The company's pioneering work has paved the way and encouraged the scientific community to develop new therapies for DMD," she continued. "The EMA is to be commended for recognizing the great unmet need for novel treatments for this relentlessly progressive disease."

Filippo Buccella, President of Parent Project Italy and UPPMD board member, commented, "After thirty years since the discovery of the dystrophin gene, we are finally beginning to see a change in the landscape. For the first time in the history of Duchenne, we see the path to approval for a drug to treat the underlying cause of DMD. This positive result rewards the efforts of a company that has always believed in collaboration with patients and with clinicians. The perseverance of this community made it possible to realize a dream that can give hope to the boys affected with nmDMD in Europe. Our work as a community of patients is not yet finished and we will stand ready to participate with PTC in the ensuing stages of this process and, we hope, with many other companies with new therapies for Duchenne."

PTC requested a re-examination of the CHMP's negative opinion received in January 2014. The positive opinion is based on data and subsequent analysis submitted from a 48-week, 174-patient Phase 2b double-blind, placebo controlled trial which demonstrated that nmDMD patients treated with Translarna (40 mg/kg given daily) walked on average 31.3 meters farther than patients on placebo, as measured by the change in six-minute walk distance (6MWD) from baseline to Week 48. Patients receiving Translarna also demonstrated a slower rate of decline in ambulation, based on an analysis of time to 10 percent worsening in 6MWD. Safety results showed that Translarna was generally well tolerated. Serious adverse events were infrequent and none were considered to be related to Translarna. PTC's global Phase 3 ACT DMD clinical trial is ongoing with full enrollment expected mid-2014.

"The positive opinion from the CHMP recommending the conditional approval of Translarna in nonsense mutation Duchenne muscular dystrophy is a major milestone for the DMD community and we are extremely proud of this joint achievement in accelerating the access to Translarna for patients with nonsense mutation DMD," stated Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics, Inc. "DMD is a progressive disease for which there are currently no approved treatment options. As previously disclosed, we expect to have all patients enrolled in our global Phase 3 ACT DMD by mid-2014. The outcome of this trial is critical for achieving full approval in the EU as well as the US. Assuming that the EC approves a conditional marketing authorization for Translarna in nmDMD, today's decision means that in parallel to this effort, we will be able to provide patients access to Translarna with the immediacy that DMD deserves."

About Conditional Approval
Conditional approval is granted based on a positive benefit/risk ratio in the available data which, while not yet comprehensive, indicate that the public health benefits of immediate availability of a medicine outweigh its risks. The company is given obligations to fulfill by the EC, such as the performance of further studies. The approval is renewed on a yearly basis until all obligations have been fulfilled, and is then converted from a conditional approval into a full approval. Conditional approvals can only be granted for medicines that satisfy an unmet medical need, meaning the medicine is intended to be used for a disease or condition for which no treatment is readily available, and it is therefore important that patients have early access to the medicine concerned.

About TranslarnaTM (ataluren)
Translarna, discovered and developed by PTC Therapeutics, Inc., is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein. The resulting disorder is determined by which protein cannot be expressed in its entirety and is no longer functional, such as dystrophin in Duchenne muscular dystrophy. The development of Translarna has been supported by grants from Cystic Fibrosis Foundation Therapeutics Inc. (the nonprofit affiliate of the Cystic Fibrosis Foundation); Muscular Dystrophy Association; FDA's Office of Orphan Products Development; National Center for Research Resources; National Heart, Lung, and Blood Institute; and Parent Project Muscular Dystrophy.

About Duchenne Muscular Dystrophy (DMD)
Primarily affecting males, Duchenne muscular dystrophy (DMD) is a progressive muscle disorder caused by the lack of functional dystrophin protein. Dystrophin is critical to the structural stability of skeletal, diaphragm, and heart muscles. Patients with DMD, the more severe form of the disorder, lose the ability to walk as early as age 10 and experience life-threatening lung and heart complications in their late teens and twenties. It is estimated that a nonsense mutation is the cause of DMD in approximately 13% of patients, or approximately 2,000 patients in the United States and 2,500 patients in the European Union. More information about DMD is available through the Muscular Dystrophy Association (www.mdausa.org), Parent Project Muscular Dystrophy (www.parentprojectmd.org), Action Duchenne (www.actionduchenne.org), United Parent Projects Muscular Dystrophy (uppmd.org), Muscular Dystrophy Campaign (www.muscular-dystrophy.org) and AFM (l'Association francaise contre les myopathies), (www.afm-telethon.fr).

About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and in collaborations with leading biopharmaceutical companies. For more information on the company, please visit our website www.ptcbio.com.

Forward Looking Statements:
All statements, other than those of historical fact, contained in this press release, including statements regarding the future expectations, plans and prospects for PTC, the timing of regulatory approvals, including any determination (whether positive or negative) by the European Commission with respect to conditional marketing authorization for Translarna in nmDMD, the development of and potential market for Translarna, including our estimates regarding the size of the nmDMD patient population, our Phase 3 clinical trial for Translarna in nmDMD, including the timing of enrollment for such trial, our ability to satisfy the obligations necessary to obtain full approval for Translarna in nmDMD, and the objectives of management, are forward-looking statements. Other forward-looking statements may be identified by the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan" "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.

Our actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements we make as a result of a variety of risks and uncertainties, including among others, those related to our expectations for regulatory approvals, including the European Commission's determination with respect to conditional marketing authorization for Translarna in nmDMD, the initiation and conduct of clinical trials, availability of data from clinical trials, our scientific approach and general development progress, the availability or commercial potential of our product candidates, market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, and the other factors discussed in the "Risk Factors" section of our most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission. You are urged to carefully consider all such factors. In addition, the forward-looking statements included in this press release represent our views only as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while PTC may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing PTC's views as of any date subsequent to the date of this press release.
http://www.wallstreet-online.de/nachricht/...-for-translarna-ataluren
-----------
Jeder ist für sein Handeln selbst verantwortlich. Keine Kaufs-/Verkaufsempfehlung !!!
Im Unterschied zur Straßenbahn wird an der Börse zum Ein- und Aussteigen nicht geklingelt.

23.05.14 14:34

1455 Postings, 4438 Tage apfelrückendirekte Konkurrenz von santhera

und in der eu vor santhera auf dem markt
-----------
Jeder ist für sein Handeln selbst verantwortlich. Keine Kaufs-/Verkaufsempfehlung !!!
Im Unterschied zur Straßenbahn wird an der Börse zum Ein- und Aussteigen nicht geklingelt.

23.05.14 15:02

1455 Postings, 4438 Tage apfelrückenprosensa

profitiert und es wird erwartet, dass nun auch prosensa die vereinfachte zulassung bekommen könnte
http://www.nasdaq.com/symbol/rna/premarket
prosensa erst 18% im plus

-----------
Jeder ist für sein Handeln selbst verantwortlich. Keine Kaufs-/Verkaufsempfehlung !!!
Im Unterschied zur Straßenbahn wird an der Börse zum Ein- und Aussteigen nicht geklingelt.

23.05.14 15:06

95 Postings, 2633 Tage Sensenbachdas war knapp

ich hätte PCT gestern fasst verkauft!  

23.05.14 15:07

1455 Postings, 4438 Tage apfelrückenprosensa

Prosensa (RNA) shares are up 16% to $7.70 in sympathy, and rightfully so. If European drug regulators are going soft on DMD drugs with spotty clinical data, then surely Prosensa's drisapersen has an excellent shot at conditional approval for exon 51 skip DMD patients.

-----------
Jeder ist für sein Handeln selbst verantwortlich. Keine Kaufs-/Verkaufsempfehlung !!!
Im Unterschied zur Straßenbahn wird an der Börse zum Ein- und Aussteigen nicht geklingelt.

23.05.14 15:08

1455 Postings, 4438 Tage apfelrückenthestreet

http://www.thestreet.com/story/12720041/1/...a-rises-in-sympathy.html
-----------
Jeder ist für sein Handeln selbst verantwortlich. Keine Kaufs-/Verkaufsempfehlung !!!
Im Unterschied zur Straßenbahn wird an der Börse zum Ein- und Aussteigen nicht geklingelt.

23.05.14 15:08

1455 Postings, 4438 Tage apfelrückenGlückwunsch sensenbach

-----------
Jeder ist für sein Handeln selbst verantwortlich. Keine Kaufs-/Verkaufsempfehlung !!!
Im Unterschied zur Straßenbahn wird an der Börse zum Ein- und Aussteigen nicht geklingelt.

23.05.14 15:16

1455 Postings, 4438 Tage apfelrückenprosensa rt 8,20$

premarket
+ 21%
-----------
Jeder ist für sein Handeln selbst verantwortlich. Keine Kaufs-/Verkaufsempfehlung !!!
Im Unterschied zur Straßenbahn wird an der Börse zum Ein- und Aussteigen nicht geklingelt.

23.05.14 16:37

1372 Postings, 3767 Tage batscherderfliesenhallo,zusammen

hat jemand RT kurse aus USA ??


danke  

25.05.14 22:36

95 Postings, 2633 Tage SensenbachHift das weiter?

http://www.marketwatch.com/investing/Stock/PTCT?countrycode=US

Ich bin gespannt wie der Kurs sich weiter entwickelt.  

02.06.14 17:55

1372 Postings, 3767 Tage batscherderfliesenSensenbach:

danke,der hilft mir gut .
 

10.12.14 11:27

1455 Postings, 4438 Tage apfelrückenHat sich schön entwickelt. Weiter so

-----------
Jeder ist für sein Handeln selbst verantwortlich. Keine Kaufs-/Verkaufsempfehlung !!!
Im Unterschied zur Straßenbahn wird an der Börse zum Ein- und Aussteigen nicht geklingelt.

27.05.15 09:35

2 Postings, 2172 Tage EykenUnd wie geht es jetzt weiter?

Die Frage ist jetzt nur, wie es nach diesem Kurssturz weiter gehen soll? Ob da noch ein weiterer Rücksetzer kommt?  

30.10.15 16:55

684 Postings, 2761 Tage husky113jetzt einstiegskurse oder noch dax rutsch abwarten

24.02.16 02:46

1452 Postings, 3962 Tage AdvamillionärWarum der...

...heftige Kurssturz gestern?

Kennt jemand den Grund?  

24.02.16 05:51
2

2772 Postings, 2451 Tage iwanoozees geht darum!

es geht um eine vererbare krankheit!Duchenne muscular dystrophy (nmDMD),und diese wurde von der FDA so bekannt gegeben!
Der FDA stellt fest, dass die Anwendung nicht genug abgeschlossen war, um eine substantivische Rezension zu erlauben .
es gab schon bei zwei anderen unternehmen,dass selbe schicksal die um die bekämpfung von MUSKESCHWUND arbeiten!
SAREPTA,hier gabs genau das selbe schreiben von der FDA,daher der absturz!
http://www.ariva.de/sarepta_therapeutics-aktie
BIOMARIN genau das selbe,nur Biomarin ist gut aufgestellt,daher kann sie sich gut fangen!
http://www.reuters.com/article/...RSS&feedName=rbssHealthcareNews

bei PTC Sollte man achten,wie die Pipeline ist,die zahlen usw.... , bevor man hier einsteigt!
 

25.02.16 19:15

1452 Postings, 3962 Tage AdvamillionärVIELEN DANK iwanooze!

Bin nach reiflichem Überlegen heute rein, da es nach einer Bodenbildung nach dem Absturz aussieht.

Extrem hoch sind die Umsätze, unglaublich, was bei dieser Aktie an zig Millionen Dollars bewegt wird

Ich denke und glaube mal, das  diese "große Aktie" bald wieder bessere Zeiten sehe wird.

Gruß vom
Advamillionär  

04.03.16 22:27

1372 Postings, 3767 Tage batscherderfliesenob das nochmal was wird????

07.03.16 16:43

1372 Postings, 3767 Tage batscherderfliesensie zuckt schon mal nach süden.

07.03.16 17:05

3633 Postings, 3320 Tage Monaco1bin heute auch rein mit einer kleinen Posi

07.03.16 17:15

1372 Postings, 3767 Tage batscherderfliesenhoffen wir mal das es gut geht.

14.03.16 21:58

3633 Postings, 3320 Tage Monaco1News

15.03.16 19:48

3633 Postings, 3320 Tage Monaco1Noch jemand dabei?

Was ist da heute los?  

02.04.16 01:29
1

1452 Postings, 3962 Tage AdvamillionärHaben wir hier...

...den Tiefpunkt endgültig hinter uns?

Ich denke ja, das Erholungspotenziel ist riesig. Leider bin ich deutlich zu früh hier eingestiegen, so das für mich erstmal Verlustabbau angesagt ist...

Gruß vom
Advamillionär  

Seite:
| 2 | 3 | 4 | 5 | 6 | 7 | 8 | 8   
   Antwort einfügen - nach oben
Werbung

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln